Quantum BioPharma stock falls after clinical trial report release

Published 05/08/2025, 15:00
© Reuters.

Investing.com -- Quantum BioPharma Ltd (NASDAQ:QNTM) stock fell 2.5% following the announcement of its Phase 1 clinical study report for Lucid-MS, a multiple sclerosis treatment candidate.

The company reported that its subsidiary, Huge Biopharma Australia, received the clinical study report (CSR) for its Phase 1 trial evaluating the safety and pharmacokinetics of Lucid-MS in healthy adult participants. According to the report, the multiple ascending dose study showed no safety or tolerability concerns in healthy participants following consecutive daily dosing.

Lucid-MS is described as a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for treating multiple sclerosis. The patented New Chemical Entity has demonstrated the ability to prevent demyelination in preclinical models, a characteristic damage to the myelin sheath surrounding nerve fibers seen in MS and other neurodegenerative diseases.

Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma, stated that the CSR is a critical component for the company’s investigational new drug application with the FDA and will allow them to advance the clinical development of Lucid-MS.

Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and Professor at University of Toronto, who led the discovery of Lucid-MS, added that the company is preparing to launch efficacy trials in patients with MS following these first-in-human studies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.